Cargando…

Editorial: Measurable residual disease in hematologic malignancies

Detalles Bibliográficos
Autores principales:	Buccisano, Francesco, Palmieri, Raffaele, Guzman, Monica L., Galimberti, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206393/ https://www.ncbi.nlm.nih.gov/pubmed/37234991 http://dx.doi.org/10.3389/fonc.2023.1204393

Ejemplares similares

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

Editorial: Epidemiological trends in hematological malignancies
por: de Lima, Marcos, et al.
Publicado: (2023)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Editorial: Case reports in hematological malignancies: 2022
por: Antar, Ahmad, et al.
Publicado: (2023)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

Editorial: Linking cellular metabolism to hematological malignancies
por: He, Xiujing, et al.
Publicado: (2022)

Editorial: The management of hematologic malignancies in lower-income countries
por: Ganesan, Prasanth, et al.
Publicado: (2023)

Editorial: Deciphering the bone marrow microenvironment in hematologic malignancies
por: Wobus, Manja, et al.
Publicado: (2023)

Editorial: COVID-19 and hematological malignancies: Volume II
por: Wilde, Lindsay, et al.
Publicado: (2022)

Editorial: The Emerging Role for PP2A in Hematologic Malignancies
por: Ruvolo, Peter P.
Publicado: (2016)

Editorial: Real-world data and real-world evidence in hematologic malignancies
por: Malagola, Michele, et al.
Publicado: (2023)

Editorial: Characteristics and behaviors of hematopoietic stem cells and leukemia stem cells in hematologic malignancies
por: Zhang, Haojian, et al.
Publicado: (2022)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Editorial: New emerging functions of transcription factors and RNA-binding proteins in the development of hematological malignancies
por: Möröy, Tarik, et al.
Publicado: (2023)

Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology
por: Moisoiu, Vlad, et al.
Publicado: (2019)

The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice
por: Galimberti, Sara, et al.
Publicado: (2019)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

WNT Signaling in Hematological Malignancies
por: Frenquelli, Michela, et al.
Publicado: (2020)

Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link?
por: Cumbo, Cosimo, et al.
Publicado: (2022)

Cap-Independent Translation in Hematological Malignancies
por: Horvilleur, Emilie, et al.
Publicado: (2015)

Multiple Roles of Glycans in Hematological Malignancies
por: Pang, Xingchen, et al.
Publicado: (2018)

PHF6 Mutations in Hematologic Malignancies
por: Kurzer, Jason H., et al.
Publicado: (2021)

The hedgehog pathway in hematopoiesis and hematological malignancy
por: Lemos, Tucker, et al.
Publicado: (2022)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
por: Barbato, Alessandro, et al.
Publicado: (2020)

Germline and somatic drivers in inherited hematologic malignancies
por: Zoller, Julian, et al.
Publicado: (2023)

Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies
por: Zuo, Fengli, et al.
Publicado: (2022)

Arginase: Mechanisms and Clinical Application in Hematologic Malignancy
por: Du, Zefan, et al.
Publicado: (2022)

Advances in the Study of circRNAs in Hematological Malignancies
por: Du, Jingyi, et al.
Publicado: (2022)

Liquid biopsies and minimal residual disease in myeloid malignancies
por: Allam, Sabine, et al.
Publicado: (2023)

Liquid biopsies and minimal residual disease in lymphoid malignancies
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Editorial: Real-World evidence in onco-hematological patients
por: Vener, Claudia, et al.
Publicado: (2022)

Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020
por: Mangone, Lucia, et al.
Publicado: (2023)

Liquid biopsy in hematological malignancies: current and future applications
por: Talotta, Donatella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_04tel5mnfbir699q09r40510mh